arrow_back Back to App

Stem Cell Therapies Support: Access to Treatment and Research

This law extends programs supporting stem cell therapies, meaning better access to treatment for patients needing transplants. It secures funding for research and development of new treatment methods, potentially offering hope for future therapies.
Key points
Extension of funding for stem cell transplant programs until 2026, ensuring continuity of treatment.
Increased frequency of advisory council meetings to respond more quickly to patient needs and scientific advancements.
Introduction of regular scientific reviews to evaluate new therapies using adult stem cells and birthing tissues.
Commissioning a report assessing the demand for specialists in regenerative medicine, which may impact the availability of qualified personnel.
article Official text account_balance Process page
VOTING RESULTS
2021-04-15
100%
For 415
Against 2
Abstain 0
Full voting results open_in_new
Became Law
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_941
Sponsor: Rep. Matsui, Doris O. [D-CA-6]
Process start date: 2021-02-08
Voting date: 2021-04-15
Meeting no: 1
Voting no: 109
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

TRANSPLANT Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_941.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-02-08.

What are the main provisions?

Key points include:

  • Extension of funding for stem cell transplant programs until 2026, ensuring continuity of treatment.
  • Increased frequency of advisory council meetings to respond more quickly to patient needs and scientific advancements.
  • Introduction of regular scientific reviews to evaluate new therapies using adult stem cells and birthing tissues.
  • Commissioning a report assessing the demand for specialists in regenerative medicine, which may impact the availability of qualified personnel.
What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-6].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-15.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health